Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C10H12N2O8.Ca.2Na.2H2O |
| Molecular Weight | 410.299 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
O.O.[Na+].[Na+].[Ca++].[O-]C(=O)CN(CCN(CC([O-])=O)CC([O-])=O)CC([O-])=O
InChI
InChIKey=JCQNARRMQCMKAN-UHFFFAOYSA-J
InChI=1S/C10H16N2O8.Ca.2Na.2H2O/c13-7(14)3-11(4-8(15)16)1-2-12(5-9(17)18)6-10(19)20;;;;;/h1-6H2,(H,13,14)(H,15,16)(H,17,18)(H,19,20);;;;2*1H2/q;+2;2*+1;;/p-4
DescriptionSources: https://www.webmd.com/balance/tc/chelation-therapy-topic-overview#1 | https://www.empowerpharmacy.com/drugs/edetate-disodium-injection.htmlhttp://umm.edu/health/medical/altmed/supplement/ethylenediaminetetraacetic-acidCurator's Comment: description was created based on several sources, including, http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5508a3.htm
Sources: https://www.webmd.com/balance/tc/chelation-therapy-topic-overview#1 | https://www.empowerpharmacy.com/drugs/edetate-disodium-injection.htmlhttp://umm.edu/health/medical/altmed/supplement/ethylenediaminetetraacetic-acid
Curator's Comment: description was created based on several sources, including, http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5508a3.htm
Edetic acid (EDTA) is a chelating agent. The U.S. Food and Drug Administration (FDA) approved edetic acid chelation therapy as a treatment for lead and heavy metal poisoning. Edetic acid in form of disodium salt was withdrawn from the market due to death resulting from hypocalcemia during chelation.
Originator
Sources: https://www.researchgate.net/publication/321552574_Ferdinand_Munz_EDTA_and_40_years_of_inventionshttps://www.google.com/patents/US2130505
Curator's Comment: Edetic acid was synthesized by Ferdinand Munz.
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: divalent and trivalent metals |
|||
Target ID: CHEMBL2364029 |
18.3 null [pKd] |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Curative | Calcium disodium versenate Approved UseEdetate calcium disodium is indicated for the reduction of blood levels and depot stores of lead in lead poisoning (acute and chronic) and lead encephalopathy, in both pediatric populations and adults. Launch Date1953 |
|||
| Curative | Calcium Disodium Versenate Approved UseEdetate calcium disodium is indicated for the reduction of blood levels and depot stores of lead in lead poisoning (acute and chronic) and lead encephalopathy, in both pediatric populations and adults. Launch Date1953 |
|||
| Curative | Unknown Approved UseUnknown |
|||
| Curative | Unknown Approved UseUnknown |
|||
| Diagnostic | Unknown Approved UseUnknown |
Cmax
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
51 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3096624 |
1 g single, intramuscular dose: 1 g route of administration: Intramuscular experiment type: SINGLE co-administered: |
EDETATE CALCIUM DISODIUM serum | Homo sapiens population: UNKNOWN age: ADULT sex: MALE food status: UNKNOWN |
T1/2
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
60 min |
unknown, unknown |
EDETATE CALCIUM DISODIUM plasma | Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN |
Doses
| Dose | Population | Adverse events |
|---|---|---|
25 mg/kg 2 times / day multiple, intravenous Recommended Dose: 25 mg/kg, 2 times / day Route: intravenous Route: multiple Dose: 25 mg/kg, 2 times / day Co-administed with:: 2,3-dimercapto-1-propanol, i.v(3 mg/kg; 6/day; 5 days) Sources: |
unhealthy, 1-8 n = 130 Health Status: unhealthy Condition: Plumbism Age Group: 1-8 Sex: M+F Population Size: 130 Sources: |
Disc. AE: Acute renal failure... Other AEs: Nephrotoxicity... AEs leading to discontinuation/dose reduction: Acute renal failure (3%) Other AEs:Nephrotoxicity (mild, 13%) Sources: |
160 mg/kg single, intravenous Studied dose Dose: 160 mg/kg Route: intravenous Route: single Dose: 160 mg/kg Sources: Page: p.361 |
unhealthy, 49 n = 1 Health Status: unhealthy Condition: Hypercalcemia|Multiple myeloma Age Group: 49 Sex: F Population Size: 1 Sources: Page: p.361 |
Disc. AE: Hypocalcemia... AEs leading to discontinuation/dose reduction: Hypocalcemia Sources: Page: p.361 |
400 mg/kg 1 times / day multiple, intravenous (max) Highest studied dose Dose: 400 mg/kg, 1 times / day Route: intravenous Route: multiple Dose: 400 mg/kg, 1 times / day Sources: Page: p.360 |
unhealthy, 58 n = 1 Health Status: unhealthy Condition: Hypercalcemia|Breast cancer Age Group: 58 Sex: F Population Size: 1 Sources: Page: p.360 |
Disc. AE: Restlessness, Hypocalcemia... AEs leading to discontinuation/dose reduction: Restlessness Sources: Page: p.360Hypocalcemia |
400 mg/kg 1 times / day multiple, intravenous (max) Highest studied dose Dose: 400 mg/kg, 1 times / day Route: intravenous Route: multiple Dose: 400 mg/kg, 1 times / day Sources: Page: p.360 |
unhealthy, 58 n = 1 Health Status: unhealthy Condition: Hypercalcemia|Breast cancer Age Group: 58 Sex: F Population Size: 1 Sources: Page: p.360 |
Disc. AE: Headache... AEs leading to discontinuation/dose reduction: Headache Sources: Page: p.360 |
AEs
| AE | Significance | Dose | Population |
|---|---|---|---|
| Acute renal failure | 3% Disc. AE |
25 mg/kg 2 times / day multiple, intravenous Recommended Dose: 25 mg/kg, 2 times / day Route: intravenous Route: multiple Dose: 25 mg/kg, 2 times / day Co-administed with:: 2,3-dimercapto-1-propanol, i.v(3 mg/kg; 6/day; 5 days) Sources: |
unhealthy, 1-8 n = 130 Health Status: unhealthy Condition: Plumbism Age Group: 1-8 Sex: M+F Population Size: 130 Sources: |
| Nephrotoxicity | mild, 13% | 25 mg/kg 2 times / day multiple, intravenous Recommended Dose: 25 mg/kg, 2 times / day Route: intravenous Route: multiple Dose: 25 mg/kg, 2 times / day Co-administed with:: 2,3-dimercapto-1-propanol, i.v(3 mg/kg; 6/day; 5 days) Sources: |
unhealthy, 1-8 n = 130 Health Status: unhealthy Condition: Plumbism Age Group: 1-8 Sex: M+F Population Size: 130 Sources: |
| Hypocalcemia | Disc. AE | 160 mg/kg single, intravenous Studied dose Dose: 160 mg/kg Route: intravenous Route: single Dose: 160 mg/kg Sources: Page: p.361 |
unhealthy, 49 n = 1 Health Status: unhealthy Condition: Hypercalcemia|Multiple myeloma Age Group: 49 Sex: F Population Size: 1 Sources: Page: p.361 |
| Hypocalcemia | Disc. AE | 400 mg/kg 1 times / day multiple, intravenous (max) Highest studied dose Dose: 400 mg/kg, 1 times / day Route: intravenous Route: multiple Dose: 400 mg/kg, 1 times / day Sources: Page: p.360 |
unhealthy, 58 n = 1 Health Status: unhealthy Condition: Hypercalcemia|Breast cancer Age Group: 58 Sex: F Population Size: 1 Sources: Page: p.360 |
| Restlessness | Disc. AE | 400 mg/kg 1 times / day multiple, intravenous (max) Highest studied dose Dose: 400 mg/kg, 1 times / day Route: intravenous Route: multiple Dose: 400 mg/kg, 1 times / day Sources: Page: p.360 |
unhealthy, 58 n = 1 Health Status: unhealthy Condition: Hypercalcemia|Breast cancer Age Group: 58 Sex: F Population Size: 1 Sources: Page: p.360 |
| Headache | Disc. AE | 400 mg/kg 1 times / day multiple, intravenous (max) Highest studied dose Dose: 400 mg/kg, 1 times / day Route: intravenous Route: multiple Dose: 400 mg/kg, 1 times / day Sources: Page: p.360 |
unhealthy, 58 n = 1 Health Status: unhealthy Condition: Hypercalcemia|Breast cancer Age Group: 58 Sex: F Population Size: 1 Sources: Page: p.360 |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Edta chelation therapy: an ethical problem. | 1999 Jul |
|
| Chelation of zinc amplifies induction of growth hormone mRNA levels in cultured rat pituitary tumor cells. | 2000 Feb |
|
| Evaluation of copper availability to plants in copper-contaminated vineyard soils. | 2001 |
|
| Fructose-6-phosphate aldolase is a novel class I aldolase from Escherichia coli and is related to a novel group of bacterial transaldolases. | 2001 Apr 6 |
|
| Anti-Saccharomyces cerevisiae antibodies (ASCA), phenotypes of IBD, and intestinal permeability: a study in IBD families. | 2001 Feb |
|
| Binding sites for progastrin-derived peptides in colonic crypts. | 2001 Feb |
|
| Simultaneous determination of 226Ra and 210Pb in groundwater and soil samples by using the liquid scintillation counter-suspension gel method. | 2001 Feb |
|
| Pharmacological characterization and antithrombotic effect of agkistin, a platelet glycoprotein Ib antagonist. | 2001 Feb |
|
| Determination of glomerular filtration rate per unit renal volume using computerized tomography: correlation with conventional measures of total and divided renal function. | 2001 Feb |
|
| Progression of diabetic nephropathy. | 2001 Feb |
|
| Cabbage cryoprotectin is a member of the nonspecific plant lipid transfer protein gene family. | 2001 Feb |
|
| Ethylenediamine-N,N,N',N'-tetraacetic acid induces parthenogenetic activation of porcine oocytes at the germinal vesicle stage, leading to formation of blastocysts. | 2001 Feb |
|
| Characterization of a model compound for the lysine tyrosylquinone cofactor of lysyl oxidase. | 2001 Feb 16 |
|
| Role of copper ions and cytochrome P450 in the vasodilator actions of the nitroxyl anion generator, Angeli's salt, on rat aorta. | 2001 Feb 2 |
|
| Differential inhibitory mechanism of Fe2+ and Fe3+ on contraction of ileal longitudinal smooth muscle. | 2001 Jan |
|
| Use of an orally administered combined sugar solution to evaluate intestinal absorption and permeability in cats. | 2001 Jan |
|
| Molecular cloning and expression of an alpha-mannosidase gene in Mycobacterium tuberculosis. | 2001 Jan |
|
| Intestinal permeability in Behçet's syndrome. | 2001 Jan |
|
| Inhibition of CaT1 channel activity by a noncompetitive IP3 antagonist. | 2001 Jan 12 |
|
| Non-oxidative mechanisms are responsible for the induction of mutagenesis by reduction of Cr(VI) with cysteine: role of ternary DNA adducts in Cr(III)-dependent mutagenesis. | 2001 Jan 16 |
|
| Determination of metal complexes of ethylenediaminetetraacetate in the presence of organic matter by high-performance liquid chromatography. | 2001 Jan 5 |
|
| Predicting the kinetics of peptide-antibody interactions using a multivariate experimental design of sequence and chemical space. | 2001 Jan-Feb |
|
| Duration of sample storage dramatically alters expression of the human immunodeficiency virus coreceptors CXCR4 and CCR5. | 2001 Mar |
|
| Adherence of Giardia lamblia trophozoites to Int-407 human intestinal cells. | 2001 Mar |
|
| Quaternary ammoniums and other preservatives' contribution in oxidative stress and apoptosis on Chang conjunctival cells. | 2001 Mar |
|
| The CDTA-soluble pectic substances from soybean meal are composed of rhamnogalacturonan and xylogalacturonan but not homogalacturonan. | 2001 Mar |
|
| Zinc release from the CH2C6 zinc finger domain of FILAMENTOUS FLOWER protein from Arabidopsis thaliana induces self-assembly. | 2001 Mar 9 |
|
| EDTA redistribution of lead and cadmium into the soft tissues in a human with a high lead burden - should DMSA always be used to follow EDTA in such cases? | 2011 Jun |
Sample Use Guides
hypercalcemia: adults: 50 mg/kg/day (up to 3 g/day) administered by slow IV infusion. Frequency and duration of administration are quite variable, and should be determined based on the patient's serum calcium. Five consecutive daily doses may be administered, followed by 2 days without medication, repeating these courses as necessary to a total of 15 doses.
Route of Administration:
Other
| Name | Type | Language | ||
|---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
CFR |
21 CFR 176.170
Created by
admin on Fri Dec 15 15:05:21 GMT 2023 , Edited by admin on Fri Dec 15 15:05:21 GMT 2023
|
||
|
CFR |
21 CFR 172.120
Created by
admin on Fri Dec 15 15:05:21 GMT 2023 , Edited by admin on Fri Dec 15 15:05:21 GMT 2023
|
||
|
NCI_THESAURUS |
C360
Created by
admin on Fri Dec 15 15:05:21 GMT 2023 , Edited by admin on Fri Dec 15 15:05:21 GMT 2023
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
DTXSID20217976
Created by
admin on Fri Dec 15 15:05:21 GMT 2023 , Edited by admin on Fri Dec 15 15:05:21 GMT 2023
|
PRIMARY | |||
|
25IH6R4SGF
Created by
admin on Fri Dec 15 15:05:21 GMT 2023 , Edited by admin on Fri Dec 15 15:05:21 GMT 2023
|
PRIMARY | |||
|
46245300
Created by
admin on Fri Dec 15 15:05:21 GMT 2023 , Edited by admin on Fri Dec 15 15:05:21 GMT 2023
|
PRIMARY | |||
|
23411-34-9
Created by
admin on Fri Dec 15 15:05:21 GMT 2023 , Edited by admin on Fri Dec 15 15:05:21 GMT 2023
|
NON-SPECIFIC STOICHIOMETRY | |||
|
1903
Created by
admin on Fri Dec 15 15:05:21 GMT 2023 , Edited by admin on Fri Dec 15 15:05:21 GMT 2023
|
PRIMARY | RxNorm | ||
|
SUB73104
Created by
admin on Fri Dec 15 15:05:21 GMT 2023 , Edited by admin on Fri Dec 15 15:05:21 GMT 2023
|
PRIMARY | |||
|
1232006
Created by
admin on Fri Dec 15 15:05:21 GMT 2023 , Edited by admin on Fri Dec 15 15:05:21 GMT 2023
|
PRIMARY | |||
|
DBSALT002785
Created by
admin on Fri Dec 15 15:05:21 GMT 2023 , Edited by admin on Fri Dec 15 15:05:21 GMT 2023
|
PRIMARY | |||
|
100000136044
Created by
admin on Fri Dec 15 15:05:21 GMT 2023 , Edited by admin on Fri Dec 15 15:05:21 GMT 2023
|
PRIMARY | |||
|
25IH6R4SGF
Created by
admin on Fri Dec 15 15:05:21 GMT 2023 , Edited by admin on Fri Dec 15 15:05:21 GMT 2023
|
PRIMARY | |||
|
CHEMBL1200375
Created by
admin on Fri Dec 15 15:05:21 GMT 2023 , Edited by admin on Fri Dec 15 15:05:21 GMT 2023
|
PRIMARY | |||
|
4757
Created by
admin on Fri Dec 15 15:05:21 GMT 2023 , Edited by admin on Fri Dec 15 15:05:21 GMT 2023
|
PRIMARY | |||
|
6766-87-6
Created by
admin on Fri Dec 15 15:05:21 GMT 2023 , Edited by admin on Fri Dec 15 15:05:21 GMT 2023
|
PRIMARY | |||
|
C334
Created by
admin on Fri Dec 15 15:05:21 GMT 2023 , Edited by admin on Fri Dec 15 15:05:21 GMT 2023
|
PRIMARY | |||
|
EDETATE CALCIUM DISODIUM
Created by
admin on Fri Dec 15 15:05:21 GMT 2023 , Edited by admin on Fri Dec 15 15:05:21 GMT 2023
|
PRIMARY | Description: A white or creamy white powder; almost odourless. Solubility: Soluble in 2 parts of water; very slightly soluble in ethanol (~750 g/l) TS; practically insoluble in in ether R. Category: Antidote, chelating agent for metals, mainly lead. Storage: Sodium calcium edetate should be kept in a tightly closed container. Additional information: Even in the absence of light, Sodium calcium edetate is gradually degraded on exposure to a humid atmosphere, the decomposition being faster at higher temperatures. Definition: Sodium calcium edetate contains not less than 97.0% and not more than 102.0% of C10H12CaN2Na2O8, calculated with reference to the anhydrous substance. |
ACTIVE MOIETY
SUBSTANCE RECORD
